Back to Report Store Home

Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

  • Published: Jul-2010
  • Report Code: GBIHC039MR
  • Report Format: pdf

Description

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 GBI Research Report Guidance

3 Market Characterization: Global Epigenetics Market

3.1 Disease Overview

3.1.1 Myelodysplastic Syndrome

3.1.2 Cutaneous T-cell Lymphoma

3.2 Epigenetic Drugs

3.3 The US

3.4 Top Five European Markets

3.5 Japan

4 In-Depth Analysis

4.1 Introduction

4.2 Vidaza (Azacitidine)

4.2.1 Indication

4.2.2 Mechanism of Action

4.2.3 Revenue Forecast

4.2.4 Key Takeaway

4.2.5 Market Potential

4.2.6 Key Takeaway

4.2.7 Pipeline Analysis

4.2.8 Key takeaway

4.2.9 Drug Profile

4.3 Dacogen (Decitabine)

4.3.1 Indication

4.3.2 Mechanism of action

4.3.3 Revenue Forecast

4.3.4 Key Takeaway

4.3.5 Market Potential

4.3.6 Key Takeaway

4.3.7 Pipeline Analysis

4.3.8 Key Takeaway

4.3.9 Drug Profile

4.4 Zolinza (Vorinostat)

4.4.1 Indication

4.4.2 Mechanism of Action

4.4.3 Revenue Forecast

4.4.4 Key Takeaway

4.4.5 Disease Overview

4.4.6 Market Potential

4.4.7 Key Takeaway

4.4.8 Pipeline Analysis

4.4.9 Key Takeaway

4.4.10 Drug Profile

4.5 Istodax (Romidepsin)

4.5.1 Indication

4.5.2 Disease Overview

4.5.3 Mechanism of Action

4.5.4 Market Potential

4.5.5 Key Takeaway

4.5.6 Pipeline Analysis

4.5.7 Clinical Studies by Phases

4.5.8 Clinical Studies by Indication

4.5.9 Key Takeaway

4.5.10 Drug Profile

5 Competitive Landscape

5.1 Merck & Co.

5.1.1 Company Overview

5.1.2 Business Description

5.1.3 SWOT

5.2 Celgene Corporation

5.2.1 Company Overview

5.2.2 Business Description

5.2.3 SWOT

5.3 EISAI

5.3.1 Company Overview

5.3.2 Business Description

5.3.3 SWOT

6 Epigenetic Therapeutics: Appendix

6.1 Market Definitions

6.2 Abbreviations

6.3 Research Methodology

6.3.1 Coverage

6.3.2 Secondary Research

6.3.3 Primary Research

6.3.4 Forecasts

6.3.5 Expert Panel Validation

6.4 Contact Us

6.5 Disclaimer

6.6 Sources

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards